Results 11 to 20 of about 42,543 (244)

Evolution of cell therapy for renal cell carcinoma [PDF]

Molecular Cancer
Treatment for renal cell carcinoma (RCC) has improved dramatically over the last decade, shifting from high-dose cytokine therapy in combination with surgical resection of tumors to targeted therapy, immunotherapy, and combination therapies.
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, Najla Santos Pacheco de Campos, Rabia Abbas, Renata Schmieder Pivetta, Nithyassree Murugan, Ghanbar Mahmoodi Chalbatani, Vincent D’Andrea, Wayne A. Marasco   +9 more
doaj   +2 more sources

Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma. [PDF]

Cancer Immunol Immunother, 2012
Sun J, Law GP, McKallip RJ.
europepmc   +3 more sources

Lymphokine-Activated Killer Cell Therapy [PDF]

Definitions, 2020
openaire   +2 more sources

T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma. [PDF]

Oncotarget, 2018
Quan C, Xiao J, Duan Q, Yuan P, Xue P, Lu H, Yan M, Guo D, Xu S, Zhang X, Lin X, Wang Y, Dogan S, Zhang J, Zhu F, Ke C, Liu L.   +16 more
europepmc   +3 more sources

Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease [PDF]

Blood, 1991
Roberto Foà, Mt Fierro, A Cesano, Alessandro Guarini, M Bonferroni, Donatella Raspadori, R Miniero, F. Lauria, F Gavosto   +8 more
openalex   +2 more sources

The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review

Frontiers in Pharmacology, 2021
So far, immunotherapy has been shown to have impressive effects on different cancers in clinical trials. All those immunotherapies are generally derived from three main therapeutic approaches: immune checkpoint inhibitors, immune cell vaccination, and ...
Fanming Kong, Fanming Kong, Tianqi Chen, Tianqi Chen, Xiaojiang Li, Xiaojiang Li, Yingjie Jia, Yingjie Jia   +7 more
doaj   +1 more source

PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells

OncoImmunology, 2021
Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies, comprising blocking antibodies (Abs) against checkpoint receptor “programmed-cell-death-1” (PD1) and its ligand (PD-L1), because most cases lack the required ...
Tobias Gutting, Veronika Hauber, Jens Pahl, Kay Klapproth, Wenyue Wu, Ioana Dobrota, Frank Herweck, Juliane Reichling, Laura Helm, Torsten Schroeder, Beifang Li, Philip Weidner, Tianzuo Zhan, Maximilian Eckardt, Johannes Betge, Sebastian Belle, Carsten Sticht, Timo Gaiser, Michael Boutros, Matthias P.A. Ebert, Adelheid Cerwenka, Elke Burgermeister   +21 more
doaj   +1 more source

Expression of Concern: T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma

Molecular Oncology, 2021
T‐lymphokine‐activated killer (T‐LAK) cell‐originated protein kinase (TOPK) is an emerging target with critical roles in various cancers; however, its expression and function in osteosarcoma remain unexplored.
Pichaya Thanindratarn, Ran Wei, Dylan C. Dean, Arun Singh, Noah Federman, Scott D. Nelson, Francis J. Hornicek, Zhenfeng Duan   +7 more
doaj   +1 more source

Immunoregulation of lymphokine-activated killer cells [PDF]

Clinical Immunology and Immunopathology, 1988
The in vitro effects of Concanavalin A (Con A) and prednisolone (PRD) on the cytotoxic functions of lymphocytes and the generation of lymphokine-activated killer (LAK) cells were investigated. Con A at concentrations ranging from 1 to 40 micrograms/ml did not significantly affect the cytotoxicity of LAK cells when added directly to the effector and ...
Nair, Madhavan P. N., Schwartz, Stanley A.   +1 more
openaire   +3 more sources

Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army

Future Science OA, 2019
Aim: To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.
Ricardo García-Muñoz, María-Josefa Nájera, Jesús Feliu, Judith Antón-Remírez, Enrique Ramalle-Gómara, Raquel Marín-Gorricho, Raisa Peralta, Elena Gutiérrez-Gamarra, Jessica Nuñez-Rodriguez, Ricardo Zafra-Morales, Lorea Aguinaga, María-Jose Nebot-Villacampa, Prisma-Monserrat Hernandez-Pérez, Giovanna Farfán-Quiroga, Carlos Panizo, Elena Domínguez-Garrido   +15 more
doaj   +1 more source